Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China 2024-05-14 21:41
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau 2024-05-08 08:05
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients 2024-05-02 09:23
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2023 2024-03-28 07:01
Everest Medicines Announces Singapore Health Sciences Authority Approves NEFEGAN® for the Treatment of Primary IgA Nephropathy in Adult Patients 2024-03-20 09:16
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer 2024-03-18 09:00
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon® 2024-03-12 09:28
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau 2024-03-11 09:00
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024 2024-03-06 08:59
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis 2024-02-27 07:14
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis 2024-02-22 08:59
Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine 2024-02-21 09:00
Everest Medicines Announces Termination of Collaboration Agreements with Providence 2024-02-19 08:20
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million 2024-01-22 07:50
Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline 2023-12-21 10:30
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China 2023-12-04 08:58
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis 2023-12-01 07:33
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea 2023-11-30 07:25
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients 2023-11-24 12:54
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy 2023-10-27 13:45
1 2 3 4 5 7